Gelonghui August 22?Kangchen Pharmaceutical (603590.SH) announced that recently, Beijing Kangchen Pharmaceutical Co., Ltd. has completed a phase III clinical trial of Jincao tablet, an innovative traditional Chinese medicine, in the treatment of chronic pelvic pain as a sequela of pelvic inflammatory disease.
Jincao tablet (total iridoid glycoside tablet) is an effective part preparation extracted from a single traditional Chinese medicine, and it is the first 1.2 innovative variety of traditional Chinese medicine accurately re-approved with the indication of "chronic pelvic pain, sequela of pelvic inflammatory disease". At present, there is no drug for the treatment of chronic pelvic pain in China.
According to the results of the phase II clinical trial of Jincao tablet announced by the company on April 7, 2022, Jincao tablet can significantly improve the symptoms of lower abdominal pain with mild and long-lasting effect. In terms of pain disappearance rate, after 12 weeks of continuous treatment, the pain disappearance rates of Jincao tablet high-dose group and low-dose group were 53.45% and 43.33%, which were significantly better than 11.86% of placebo group (p < 0.0001).
